Journal: Blood Advances

Article Title: Expression and treatment of ROR1 + cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia

doi: 10.1182/bloodadvances.2024013814

Figure Lengend Snippet: ROR1 is expressed in both BCP-ALL and T-ALL. (A) Proportion of ROR1 + cells and (B) number of ROR1 binding sites in 19 BCP-ALL, 10 T-ALL cases, and 6 NBM samples. Each symbol can be distinguished by MRD status (low-, intermediate-, or high-risk). Solid horizontal lines represent medians, error bars represent the interquartile ranges, and interrupted lines represent the NBM median. ∗ P ≤ .05.

Article Snippet: On termination, femoral BM was assessed by flow cytometry for human cell engraftment using antibodies against CD34, CD45, CD7, and CD19 (all from BD Biosciences) and ROR1 (Miltenyi biotec).

Techniques: Binding Assay

Journal: Blood Advances

Article Title: Expression and treatment of ROR1 + cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia

doi: 10.1182/bloodadvances.2024013814

Figure Lengend Snippet: ROR1 is coexpressed with BCP-ALL and T-ALL lineage markers. Proportion of ROR1 + cells in (A) BCP-ALL (Pts 1-19) or (B) T-ALL (Pts 20-29) and their respective LPC subpopulations. (C-D) Number of ROR1 binding sites in BCP-ALL and T-ALL and subpopulations. Each symbol represents an individual patient sample. Horizontal lines represent medians and error bars represent the interquartile ranges. ∗ P ≤ .05, ∗∗ P ≤ .01, and ∗∗∗ P ≤ .001 when directly compared to CD19 – and CD7 – subpopulations and analyzed by Kruskal-Wallis test.

Article Snippet: On termination, femoral BM was assessed by flow cytometry for human cell engraftment using antibodies against CD34, CD45, CD7, and CD19 (all from BD Biosciences) and ROR1 (Miltenyi biotec).

Techniques: Binding Assay

Journal: Blood Advances

Article Title: Expression and treatment of ROR1 + cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia

doi: 10.1182/bloodadvances.2024013814

Figure Lengend Snippet: Proliferation of ROR1 + and ROR1 – cell populations. Cells from BCP-ALL (Pts 16, 17, and 19) (A), T-ALL (Pts 20, 22, and 27) (B), and 3 NBM cases (C) were stained with proliferation marker, CTV before being cultured for 7 days. CTV MFI of ungated, ROR1 + and ROR1 – cells and subpopulations was compared between day 0 (undivided) and day 7 cells and analyzed by Kruskal-Wallis test. ∗ P = .04. Data are expressed as mean ± standard deviation (SD). MFI, median fluorescence intensity.

Article Snippet: On termination, femoral BM was assessed by flow cytometry for human cell engraftment using antibodies against CD34, CD45, CD7, and CD19 (all from BD Biosciences) and ROR1 (Miltenyi biotec).

Techniques: Staining, Marker, Cell Culture, Standard Deviation, Fluorescence

Journal: Blood Advances

Article Title: Expression and treatment of ROR1 + cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia

doi: 10.1182/bloodadvances.2024013814

Figure Lengend Snippet: ROR1 + LPC are resistant to induction therapy. Proportion of ROR1 positive cells (A-B) and number of binding sites (C-D) detected on samples at presentation (day 0), day 29, and wk 14 from BCP-ALL Pts 3, 12, and 17 (A,C) and T-ALL Pts 20 to 24 and 27 (B,D). Interrupted outlines indicate survival of ROR1 + LPC populations after induction therapy. Arrows indicate the emergence of ROR1 + in LPC. HSC, hematopoietic stem cell. Wk14, week 14.

Article Snippet: On termination, femoral BM was assessed by flow cytometry for human cell engraftment using antibodies against CD34, CD45, CD7, and CD19 (all from BD Biosciences) and ROR1 (Miltenyi biotec).

Techniques: Binding Assay

Journal: Blood Advances

Article Title: Expression and treatment of ROR1 + cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia

doi: 10.1182/bloodadvances.2024013814

Figure Lengend Snippet: ROR1-bispecific T eng reduce ALL viability. (A) BCP-ALL cells (Pts 16 and 19), T-ALL cells (Pts 22-24 and 26), and NBM cells (n = 4) were incubated 1:1 with T cells ± ROR1 T eng or CD19 T eng for 24 hours and cell viability assessed by flow cytometry. (B) IFN-γ release was measured in supernatants of cytotoxicity assays. Data represent mean ± SD. ∗ P ≤ .05, ∗∗ P ≤ .01, and ∗∗∗ P ≤ .001.

Article Snippet: On termination, femoral BM was assessed by flow cytometry for human cell engraftment using antibodies against CD34, CD45, CD7, and CD19 (all from BD Biosciences) and ROR1 (Miltenyi biotec).

Techniques: Incubation, Flow Cytometry

Journal: Blood Advances

Article Title: Expression and treatment of ROR1 + cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia

doi: 10.1182/bloodadvances.2024013814

Figure Lengend Snippet: T eng reduce leukemia burden in vivo. NSG mice were inoculated with BCP-ALL (Pts 16, 18, and 19) and T-ALL (Pt 22) samples, before being treated with T eng and T cells. (A) Engraftment levels in PB, monitored weekly by flow cytometry. Gray boxes represent duration of treatment. Data in PB graphs represent mean ± SD (n = 3-4 mice per treatment condition). (B) Proportion of ROR1 + and CD19 + cells in BM at termination. (C) IFN-γ levels in murine plasma at termination. Bars represent mean ± SD (n = 3-4).

Article Snippet: On termination, femoral BM was assessed by flow cytometry for human cell engraftment using antibodies against CD34, CD45, CD7, and CD19 (all from BD Biosciences) and ROR1 (Miltenyi biotec).

Techniques: In Vivo, Flow Cytometry, Clinical Proteomics